What Is Telisotuzumab Vedotin?
Telisotuzumab Vedotin is a drug currently under investigation in clinical trials. It is administered as an Intravenous (IV) Infusion. While the specific mechanism of action is not detailed in the provided trial descriptions, it is being studied as a potential treatment for various cancers. Research is exploring its use both as a standalone therapy and in combination with other medications.
Clinical trials for Telisotuzumab Vedotin first began on March 28, 2014, with the latest trial initiated on January 7, 2026. A total of 8 trials have been conducted or are ongoing, with 3 trials currently recruiting participants. These studies have collectively enrolled 1,424 participants to date, investigating the drug's safety and effectiveness.
Uses and Conditions Under Study
Telisotuzumab Vedotin is primarily being investigated for its potential in treating various forms of cancer. The most extensively studied condition is Non-Small Cell Lung Cancer (NSCLC), which is a common type of lung cancer. This drug is being explored as a treatment option for NSCLC across 7 trials, aiming to address this challenging disease.
Additionally, Telisotuzumab Vedotin is being studied for its effects on Advanced Solid Tumors Cancer. This category includes cancers that have spread from their original site and are typically more difficult to treat. One trial is dedicated to understanding how Telisotuzumab Vedotin might benefit patients with these advanced cancers, exploring its potential to slow disease progression or improve patient outcomes.
Dosing
Telisotuzumab Vedotin is administered as an Intravenous (IV) Infusion. Clinical trials are investigating several different dosing strategies and combinations to determine the most effective and safest approach. These include various monotherapy regimens, such as Telisotuzumab Vedotin given in 21-day dosing cycles and 28-day dosing cycles.
Different investigational doses, referred to as Telisotuzumab Vedotin Dose A, Telisotuzumab Vedotin Dose B, and Telisotuzumab Vedotin Dose C, are being studied. The drug is also being explored in combination with other therapies. Investigational arms include Telisotuzumab Vedotin plus Osimertinib, Telisotuzumab Vedotin plus Erlotinib, and Telisotuzumab Vedotin plus Nivolumab. Some trials also compare Telisotuzumab Vedotin to Docetaxel or a Standard of Care regimen.
Side Effects
Information on the side effects of Telisotuzumab Vedotin from clinical trials was not available at the time of this review. Please consult with your healthcare provider for detailed information regarding potential side effects.
Clinical Trial Results
Telisotuzumab Vedotin for Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
In a study (NCT05513703) investigating Telisotuzumab Vedotin in adult participants with advanced or metastatic non-squamous non-small cell lung cancer, several key outcomes were assessed:
- The Objective Response Rate (ORR), which measures the percentage of patients whose cancer significantly shrinks or disappears, was 33.3%.
- The Disease Control Rate (DCR), representing the percentage of patients whose cancer either shrinks, disappears, or remains stable, was 44.4%.
- Among patients who responded to treatment, the median Duration of Response (DoR) was 8.5 months.
- The median Progression-Free Survival (PFS), which is the time patients lived without their cancer getting worse, was 4.0 months.
- The median Overall Survival (OS) for participants in the study was 17.5 months.
The study also evaluated changes in symptoms and quality of life using standardized questionnaires. On average, patients experienced an improvement in cough, with a mean change of -24.46 on the EORTC QLQ-LC13 scale, where negative scores indicate improvement. Changes in dyspnea (shortness of breath) and chest pain were minimal on average. Global health status and quality of life showed a slight average improvement of +1.96 on the EORTC QLQ-C30 scale, where positive scores indicate improvement.
Currently Recruiting Trials
Telisotuzumab vedotin is currently being investigated in several clinical trials for non-small cell lung cancer (NSCLC). These studies aim to understand its safety, effectiveness, and how it compares to existing treatments. Participating in a clinical trial can offer access to new treatments and contribute to medical knowledge. One ongoing Phase II trial, sponsored by Jonsson Comprehensive Cancer Center, is studying NCT07323641. This study is testing how well telisotuzumab vedotin works in combination with osimertinib for the treatment of non-small cell lung cancer that is progressive (growing or spreading) and currently considered incurable. The trial is designed to enroll approximately 60 participants who meet specific criteria for this advanced form of lung cancer. Another Phase II study, sponsored by AbbVie, is NCT06568939. This trial focuses on assessing the safety and pharmacokinetics (how the drug moves through the body) of telisotuzumab vedotin as a single treatment. It is open to adult participants with previously treated non-squamous non-small cell lung cancer. The study plans to enroll around 150 participants across different dosage groups to gather comprehensive data. The largest ongoing study is a Phase III trial, also sponsored by AbbVie, identified as NCT04928846. This study directly compares telisotuzumab vedotin to docetaxel, a standard chemotherapy, in adult participants with previously treated non-squamous non-small cell lung cancer. Researchers are evaluating disease activity and adverse events to determine if telisotuzumab vedotin offers a better treatment option. This pivotal trial aims to enroll approximately 698 participants.Where to Participate
Clinical trials for telisotuzumab vedotin are actively recruiting across a wide geographic area, making participation accessible to many. Research sites are established in 86 locations across 64 cities and 32 states within the United States. Some of the cities with multiple participating sites include:- Los Angeles, California (4 sites)
- Honolulu, Hawaii (2 sites)
- Chandler, Arizona (2 sites)
- Ogden, Utah (2 sites)
- Springfield, Illinois (2 sites)
- York, Pennsylvania (2 sites)
- Lincoln, Nebraska (2 sites)
- Pinehurst, North Carolina (2 sites)
- Savannah, Georgia (2 sites)
- Greenville, South Carolina (2 sites)